CGT · 림프종

299개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved299 programs
CGTLimited DatastaleSouthwest Hospital, ChinaPhase 2

Anti-CD30-CAR-transduced T cells (Anti-CD30-CAR-transduced T cells)

Leukemia; Lymphoma · CD30

#CD30#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 1

Anti-CD5 CAR NK cells (Anti-CD5 CAR NK cells)

T-ALL/Lymphoma · T-ALL/Lymphoma

#T-ALLLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-Cluster of Differentiation (CD, Anti-Cluster of Differentiation, Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR))

ALL; B Cell Lymphoma · ALL

#ALL#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleJiangsu Topcel-KH Pharmaceutica…Phase 1

Anti-PD1 armored CD19 CAR-T cells (Anti-PD1 armored CD19 CAR-T cells)

Diffuse Large B Cell Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-Tumor Necrosis Factor (TNF, Anti-Tumor Necrosis Factor, Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells)

Lymphoma, Large-Cell, Anaplastic; Enteropathy-Associated T-Cell Lymphoma · CD30

#CD30#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleAFA InsurancePhase 2

Autologous 3rd generation CD19-targeting CAR T cells (Autologous 3rd generation CD19-targeting CAR T cells)

B Cell Lymphoma; B Cell Leukemia · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleMayo ClinicPhase 1

Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563 (Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563)

Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleAstraZenecaPhase 1

Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014 (Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014)

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent Diffuse Large B-Cell Lymphoma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Discontinued
CGTLimited DatastaleMayo ClinicPhase 1

Autologous BAFFR-targeting CAR T Cells (Autologous BAFFR-targeting CAR T Cells)

B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous BCMA/CD19 dual-target CAR-T module (Autologous BCMA/CD19 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous BCMA/CD38 dual-target CAR-T module (Autologous BCMA/CD38 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous BCMA/GPRC5D dual-target CAR-T (Autologous BCMA/GPRC5D dual-target CAR-T)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleInstitute of Hematology and Blo…Phase 1

Autologous CAR123 T lymphocytes (Autologous CAR123 T lymphocytes)

Leukemia, Myeloid, Acute(AML); Precursor Cell Lymphoblastic Leukemia-Lymphoma · Leukemia, Myeloid, Acute(AML)

#LeukemiaMyeloidAcuteAML#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Autologous CCR4 CAR T cells (Autologous CCR4 CAR T cells)

Relapsed and/or Refractory Mature T Cell Malignancy; Peripheral T-Cell Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD19/CD20 dual-target CAR-T module (Autologous CD19/CD20 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD19/CD22 dual-target CAR-T module (Autologous CD19/CD22 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleTessa TherapeuticsPhase 1

Autologous CD30.CAR-T (Autologous CD30.CAR-T)

Classical Hodgkin Lymphoma; Hodgkin Disease Refractory · CD30

#CD30#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD33/CD123 dual-target CAR-T module (Autologous CD33/CD123 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD33

#CD33#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD33/CLL1 dual-target CAR-T module (Autologous CD33/CLL1 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD33

#CD33#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBaylor College of MedicinePhase 1

Autologous CD5.CAR/28zeta CAR T cells (Autologous CD5.CAR/28zeta CAR T cells)

T-cell Acute Lymphoblastic Lymphoma; T-non-Hodgkin Lymphoma · T-cell Acute Lymphoblastic Lymphoma

#T-cellAcuteLymphoblasticLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting

7 / 15 pages

← PreviousNext →